A 'test and treat' strategy is advocated for patients with dyspepsia under the age of 45 years, with endoscopy reserved for those with alarm symptoms or aged over 45 years. One of the consequences of this strategy will be a reduction in population infection rates of Helicobacter pylori. It is now clear that H. pylori is one of the prime initiators of gastric cancer with up to 70% of gastric cancers attributable to H. pylori. What remains unclear is if H. pylori reduction will lead to a reduction in gastric cancer.
INTRODUCTION
A 'test and treat' strategy was recently recommended by the European Helicobacter Pylori Study Group, as the clinical approach of choice for patients under 45 years of age with dyspepsia, in the absence of alarm symptoms or a family history of gastric cancer. 1 These guidelines imply that endoscopy can be avoided in most young patients with uncomplicated dyspepsia. A recent large study demonstrated that this approach led to a dramatic reduction in the use of endoscopy in 'test and treat' patients over a 1-year period. 2 Gastric cancer remains a major public health issue. It is the second leading cause of cancer death world-wide 3 with approximately 1000 000 deaths per year. 4 The exact prevalence of Helicobacter pylori infection in gastric cancer patients is difficult to estimate because evidence of the infection can be lost with the development of gastric precancerous lesions or gastric cancer. Studies suggest that up to three-quarters of gastric cancers are attributable to H. pylori infection. 5 It now seems appropriate to ask whether a 'test and treat' strategy might help prevent gastric cancer. A 'test and treat' strategy for young patients with dyspepsia may result in significant reductions in population infection rates. An unexpected outcome of this strategy may be a reduction in gastric cancer rates. The impact of H. pylori eradication on prevention of gastric cancer is uncertain. While the link between H. pylori and gastric cancer development has been established the reversibility of precancerous lesions is still controversial. Studies assessing the effect of H. pylori eradication in gastric premalignant lesions are equivocal.
HELICOBACTER PYLORI AND GASTRIC CANCER
In 1994 H. pylori infection was classified as a definite carcinogen by the International Agency for Research on Cancer. 3 The role of H. pylori infection in the genesis of gastric cancer, however, is still controversial because there is a high population prevalence of infection yet less than 1% of infected subjects will develop gastric cancer.
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In 12 studies analysed by the Helicobacter and Cancer Collaborative Group involving 1228 patients with gastric cancer and over 3000 controls an overall Odd's ratio of 2.36 for the development of gastric cancer was found for those who were H. pylori positive. Between 65 and 80% of noncardia gastric cancer was attributable to H. pylori infection. This study also showed an association between the duration of infection and gastric cancer, with those known to be infected for more than 10 years having an Odd's ratio of 9.6 for the development of gastric cancer compared with those with a shorter duration of infection. 12 In 1994 Forman et al.
summarized all available case studies and found an increased relative risk of 3.8 for development of gastric cancer in patients with H. pylori infection. 13 More recently, Uemura et al. in a prospective study of 1526 patients showed that the risk of gastric cancer in H. pylori infected patients was 5% at 10 years. Of the 1526 patients, gastric cancer developed in 36 (2.9%) of the 1246 patients with H. pylori and in none of the 280 who were negative for infection.
14 Diagnostic tests including culture, immunohistochemistry, rapid urease test, urea breath test and detection of H. pylori in the stool all rely on the actual presence of H. pylori. These tests therefore may give a false negative result when H. pylori density in the gastric mucosa is low, as occurs in gastric atrophy, intestinal metaplasia and gastric cancer. 15, 16 Serological tests on the other hand detect evidence of both past and current infections.
PATHOGENESIS OF GASTRIC CANCER
It is hypothesized that H. pylori infection provokes a step-wise progression in gastric-mucosal pathology commencing with active gastritis and progressing to gastric atrophy, intestinal metaplasia, dysplasia and eventually gastric adenocarcinona. [17] [18] [19] This pathway was initially proposed by 23 The disturbed equilibrium of apoptosis and cell proliferation associated with H. pylori infection may lead to an overall increase in cellular turnover and persistence of mutated cells, which may in turn favour the development of neoplasia.
The reasons why only a small minority of patients with H. pylori develop gastric cancer may be related to differences in host susceptibility, environmental factors and genetic diversity of H. pylori.
HOST FACTORS
Subjects with a family history of gastric cancer have a 1.5-3-fold increased risk of developing gastric cancer. 24 This may be due to inherited factors. Interleukin-1beta is a potent pro-inflammatory cytokine and a powerful inhibitor of gastric acid secretion. Interleukin-1beta REVIEW: GASTRIC CANCER PREVENTIONpolymorphisms are associated with an increased risk of hypochlorhydria and of gastric cancer. 25 Transforming growth factor beta controls cell growth, cell differentiation and migration. Increased expression of transforming growth factor beta has been demonstrated in patients with gastric cancer and in their first degree relatives. 26 The HLA-DQA1 locus is another risk factor for gastric cancer with the absence of the haplotype DQA1*0102 being associated with an increased risk of atrophic gastritis and adenocarcinoma. 27 Microsatellite instability is also reported in patients with a family history of gastric cancer. 28 The apparent increased inherited risk of gastric cancer may, however, be due to intrafamilial clustering of H. pylori infection, which is increased in relatives of gastric cancer patients. positive infection is associated with increased production of reactive oxygen species in the gastric mucosa leading to severe oxidative DNA damage. 36 The vacA and iceA genes are associated with an increased risk of gastric cancer. 37, 38 Aside from these bacterial toxins, bacterial adherence factors such as the blood group antigen binding adhesion (babA) genes have recently been implicated in the development of gastric cancer. 39 Multiple molecular and genetic alterations have been identified in gastric cancer, including activated oncogenes, growth factors and growth factor receptors. 40, 41 Inactivated tumour suppressor genes p53, APC and k-ras are seen in 30-40%, 30% and 8% of gastric cancers, respectively. [42] [43] [44] Reactivation of telomerases such that the cells do not undergo physiological senescense has been described. 45 Other abnormalities seen in gastric cancer are up-regulation of transcription factors 46 and mutations of the E-cadherin gene or hypermethylation of the E-cadherin promoter region thus blocking the expression of E-cadherin and so affecting cell adhesion. 28, 47 Microsatellite instability due to hypermethylation, rather than mutation of the mismatch repair genes, 48 has also been described in gastric cancer.
H. PYLORI ERADICATION AND GASTRIC CANCER
Although evidence for the role of H. pylori in gastric carcinogenesis is compelling, it is not known whether eradication of infection might effectively prevent gastric cancer. There is conflicting evidence on the effect of H. pylori eradication on gastric atrophy and intestinal metaplasia. Some studies of H. pylori eradication have shown a beneficial effect on both lesions, whereas other studies have not observed any significant improvement.
Van der Hulst et al. in an uncontrolled study of 155 patients followed up for 1 year after H. pylori eradication revealed no change in gastric atrophy or in intestinal metaplasia. 49 Forbes et al. followed up 54 patients for 7 years, of whom 32 had successful H. pylori eradication.
There was no significant difference in gastric atrophy or in intestinal metaplasia between the two patient groups. 50 Annibale et al. successfully eradicated H. pylori in 25 of 32 patients. After a year there was no improvement in gastric atrophy or intestinal metaplasia. 51 In a large randomized controlled study Correa et al.
followed up 631 patients for 6 years. Patients were randomized to eight different treatments and only 79 received H. pylori eradication. Intestinal metaplasia progressed at the same rate in both the placebo (23%) and the eradicated group (17%). 52 Ohkusa et al. in an uncontrolled prospective trial, followed up 115 patients with dyspepsia and successful H. pylori eradication over 12-15 months. Glandular atrophy improved in 34 of the 38 (89%) affected patients and intestinal metaplasia improved in 21 of the 46 (61%) affected patients. 53 Sung et al. undertook a large scale prospective placebo-controlled trial in which 226 patients with H. pylori eradicated and 245 patients who remained infected with H. pylori were followed up for 1 year. Over that time a slight regression of intestinal metaplasia in the antrum was seen in the H. pylori negative group but this was not significant. Patients with persisting infection, however, had significant progression of corpus atrophy. 54 Kokkola et al.
followed up 22 patients with H. pylori infection and moderate or severe corpus gastric atrophy for 7.5 years and found no significant change in atrophy or intestinal metaplasia. H. pylori was then eradicated in all 22 patients and after 2.5 years follow up there was a significant improvement in both atrophy and intestinal metaplasia. 55 In a longer post-eradication follow up, Ito et al. in a study of 54 patients over 5 years, showed that H. pylori eradication led to a significant decrease in both gastric atrophy and intestinal metaplasia in the corpus and antrum. 56 One reason for the apparent discrepancies in the impact of H. pylori eradication on gastric atrophy or intestinal metaplasia may be the small numbers involved in most of the studies listed and the relatively short follow-up period. Those studies showing a significant improvement in gastric preneoplastic lesions following H. pylori eradication had follow up for 2-5 years. The patchy distribution of both gastric atrophy and intestinal metaplasia may also jeopardize the reliability of endoscopic and biopsy-based follow-up studies. 57 
SCREENING FOR GASTRIC CANCER
Fendrik et al. using a decision analysis model, have shown that the cost-effectiveness of H. pylori screening strategies for gastric cancer depends on the cancer reduction rate. The strategy, however, remains costeffective even at moderate rates (< 30%) of risk reduction. 58 Studies on H. pylori and gastric cancer have shown Odd's ratios for increased cancer risk varying from 2.2 to 6. This variation can be attributed to differences in the subjects enrolled, the prevalence of H. pylori infection in the population and the method of detection used. The magnitude of Odd's ratios is affected by the background prevalence of H. pylori, so that where H. pylori is highly prevalent the Odd's ratio will be lowered although the incidence of cancer will be high. 59 In addition, the diagnostic method used influences the apparent prevalence of H. pylori infection and hence the Odd's ratio of H. pylori and gastric cancer will vary depending on the tests. 60 
SCREENING FOR H. PYLORI
The effectiveness of any screening programme is dependent on the accuracy and reliability of the screening tools used. The urea breath test is considered the most accurate noninvasive method of diagnosing H. pylori infection.
Urea breath test results, expressed as the delta value, are affected by the density of H. pylori infection and by the severity of atrophic gastritis. As a result urea breath test delta values in gastric cancer patients tend to be significantly lower than in patients with gastritis, duodenal ulcer or gastric ulcer. 61 In addition the urea breath test is expensive and may not be readily available for population studies. The HpSA test detects the presence of H. pylori antigens in the stool, and similar to the urea breath test, the sensitivity of the HpSA test is affected by the density of H. pylori infection. The sensitivity and specificity of the HpSA test is at least as good as the urea breath test 62, 63 and the HpSA is less expensive than the urea breath test. One of its drawbacks is the acceptability of the test. A new stool test using monoclonal antibodies appears similar to the polyclonal HpSA. 64 Serological detection of IgG antibody against H. pylori provides a reliable assessment of current or past H. pylori infection. H. pylori infection is usually lifelong therefore a positive test usually denotes active infection unless the patient has received eradication therapy. Serology testing for H. pylori infection is sensitive and specific, approaching 95% in some studies. It is noteworthy that Cag A antibodies persist longer after H. pylori eradication than surface antibodies and so studies that used Cag A antibodies, rather than H. pylori surface antibodies, for diagnosis have raised the Odd's ratio of H. pylori leading to gastric cancer development from 2.0 to 21. 5 There are other serological tests that may prove helpful in predicting those who are at a higher risk of developing gastric cancer, including pepsinogen ratios, antiparietal cell antibodies and gastrin levels. As atrophic gastritis becomes more extensive and severe normal gastric gland function is progressively diminished. Pepsinogen exists as two types, I and II, which are both produced by the chief and mucus neck cells in the gastric fundus. Pepsinogen II is also produced by the pyloric glands in the antrum and in the proximal duodenum. With gastritis and mild inflammation both Pepsinogen I and II are increased. With more severe atrophy Pepsinogen I decreases as the chief cells are destroyed but Pepsinogen II remains elevated. When measurement of serum Pepsinogen concentrations are used as a screening test for gastric cancer, they achieve a sensitivity of > 80% and specificity of > 70%. 65 Anti-parietal cell antibody is well known as an autoantibody in pernicious anaemia. Anti-parietal cell antibody is also an auto-antibody in H. pylori associated gastritis. The level of anti-parietal cell antibody expression is associated with the histological degree of atrophic gastritis and maybe useful in predicting those who will progress to gastric atrophy. 66 Fundic atrophic gastritis leads to hypochlorhydria, which in turn leads to rebound hypergastrinaemia. Levels of serum gastrin have been used to screen for gastric cancer. In a recent case control study, Konturek et al. found elevated gastrin levels in 48% of gastric cancer patients compared with 8% of controls and found a significant correlation between the rise in serum gastrin and the rise in intragastric pH. 67 
TEST AND SCOPE
Endoscopy is a more expensive screening tool and not as well tolerated by patients. In a study of 169 patients diagnosed with gastric cancer under the age of 55 years, Gillen & Mc Coll showed that only five presented without alarm symptoms and that all five of these patients had evidence of metastasis at presentation. 68 This study suggests that, in the absence of alarm symptoms, dyspeptic symptoms in patients less than 55 years may be an appropriate age cut-off for noninvasive testing. Across Europe there is a wide variation in the national incidence of gastric cancer (per 100 000) with Portugal (31.9), Austria (21.6) and Italy (20.7) having the highest incidence and the lowest incidence in Denmark (8.9), France (10.3) and Sweden (10.6). 69 In countries with a high prevalence of H. pylori infection where the incidence of gastric cancer is also high it may be necessary to recommend endoscopy at a younger age as suggested by Dzuba et al. who proposed screening with endoscopy in those over 30 years of age in Russia. 70 One of the benefits of endoscopy is that it allows detection of precancerous lesions and also permits continued surveillance thereafter. Uemura et al. showed that among patients infected with H. pylori, those with severe gastric atrophy, intestinal metaplasia and corpus predominant gastritis were at the highest risk of developing gastric cancer. 14 
RECOMMENDATIONS
Current European guidelines suggest that in areas of low prevalence of H. pylori infection, and in the absence of alarm symptoms or a family history of gastric cancer, a 'test and treat' approach is suitable for patients aged < 45 years. In areas of high prevalence of H. pylori the age cut-off for endoscopy may need to be reduced to minimize the risk of missing early gastric cancer. H. pylori infection is a major public health issue and gastric cancer remains an important disease with a high mortality once diagnosed. Widespread population screening and eradication of H. pylori may have the potential to reduce the incidence of gastric cancer but further large scale studies are warranted to answer this question. Targeted screening and eradication of H. pylori infection, apart from alleviation of dyspepsia may have other beneficial effects and should be promoted as an important public health issue.
